ABSTRACT
In patients with chronic lymphocytic leukemia (CLL), lenalidomide can promote humoral immune responses but also induces a distinct disease-specific toxicity of tumor flare and cytokine release. These CLL-specific events result from increased expression of co-stimulatory molecules on B-cells. Here For personal use only. on October 15, 2017 . by guest www.bloodjournal.org From
INTRODUCTION
Lenalidomide is an immune modulatory agent currently approved for marketing in multiple myeloma and myelodysplasia. Lenalidomide is also clinically active in lymphoma, acute myeloid leukemia, and chronic lymphocytic leukemia (CLL) 1, 2 . The potential mechanisms of action of lenalidomide in these different diseases are multiple (reviewed in 3 ). Application of lenalidomide in CLL has been associated with development of anti-tumor antibodies and reversal of hypogammaglobulinemia 4 , but can also induce a disease-specific side effect of tumor flare and cytokine release 3, 5 16, 17 ; and the potential interest in administering these newer drugs with lenalidomide as therapy for CLL. In addition as we reported 14 , CAL-101 has a modest effect cell viability, thus the conditions used in these experiments show little effects on viability.
MATERIALS AND METHODS

Cell
Flow cytometry. Surface staining with antibodies to CD20, CD40, CD80, CD86 or IgG1 (BD Biosciences, San Jose CA) was done as previously described 4 .
Immunoblot analysis. Immunoblots were performed as previously described 20 . Antibodies included: anti-AKT, anti-phospho-AKT (Ser473), anti-GSK3β, anti-phospho-GSK3β (Ser9) (Cell Signaling, Danvers, MA), anti-p110δ (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-GAPDH (Millipore, Billerica, MA).
Quantitative RT-PCR. RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) and cDNA was prepared using a SuperScript First-Strand Synthesis System (Invitrogen) as previously described 21 . Real-Time PCR was performed using pre-designed TaqMan® Gene
Expression Assays and an ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA).
For personal use only. on October 15, 2017. by guest www.bloodjournal.org From PI3K Assay. The PI3K assay was performed on whole-cell lysates from CLL cells. The ELISA assay was performed according to the manufacturer's instructions as previously described 14 (Echelon Biosciences, Salt Lake City, UT).
siRNA Transfection. CLL cells were transfected as previously described 22 . PI3K-δ-specific siRNA (Ambion, Austin, TX) was used at a final concentration of 50nM.
Immunoglobulin detection. Quantitation of IgM was determined as previously described 4 .
Briefly, lenalidomide-treated or vehicle-treated CLL cells were irradiated and placed in culture with target, normal B-cells in the absence or presence of pokeweed mitogen (PWM) (5 µg/mL).
Statistical analysis. All reported statistical evaluations were performed with methods previously described. 14 Because the same patient samples were treated under different condition, linear mixed effects models were used for all analysis to account for the correlations of observations from the same patient. RT-PCR data was first normalized to internal controls before analysis.
Log transformation was also used for some experiments to reduce variance and skewness.
Holm's procedure was used to adjust for multiple comparisons. P-values of ≤0.05 (including those adjusted for multiple comparisons) were considered significant.
RESULTS AND DISCUSSION
Previous studies have demonstrated lenalidomide upregulates CD154 protein expression on CLL cells by activation of AKT, IKK, and by NF-κB nuclear translocation with subsequent increased mRNA transcription and stabilization without inducing cell death 4 .
Treatment of CLL cells with the pan-PI3K inhibitor LY294002 antagonized this CD154 upregulation 4 . PI3K signaling by lenalidomide could occur through any of the four catalytic isoforms of PI3K: p110α, p110β, p110γ, and p110δ. We therefore sought to determine if a specific isoform of PI3K was responsible for this. We first confirmed that lenalidomide directly increased the enzymatic activity of PI3K (p-value=0.0012) (Fig. 1A) . We found that inhibition of PI3K-δ via the p110δ-specific small-molecule inhibitor, CAL-101, prevented the increase in PI3K
For (Fig. 1A) . Next we sought to determine if inhibition of PI3K-δ with CAL-101 could prevent the increase in downstream phosphorylation of AKT induced by lenalidomide; we found that inhibition of PI3K-δ by CAL-101 prevented phospho-AKT formation (Fig. 1B) . To confirm these results we evaluated the phosphorylation of GSK3β, another downstream protein in the PI3K pathway. We found that lenalidomide provoked an increase in phospho-GSK3β that was preventable by co-treatment with CAL-101, again suggesting a link between PI3K-δ and lenalidomide-dependent PI3K activity (Fig. 1C) . To confirm that these results were in fact due to PI3K-δ inhibition, we knocked-down PI3K-δ in CLL cells (Fig 1D) . We were able to show that lenalidomide was unable to induce phosphorylation of AKT when PI3K-δ-specific siRNA was expressed (Fig 1E) . Given our desire to focus on relatively select expressed hematopoietic isoforms, we did not target p110 alpha and beta. Such investigation with pan-PI3-kinase inhibitors warrants future studies. These findings demonstrate that lenalidomide-mediated PI3K activation and subsequent effects on NF-κB and CD154 4 in CLL cells utilize a PI3K-δ-dependent pathway.
We have previously shown that lenalidomide activates CLL cells. To extend our findings, we sought to determine if inhibition of PI3K-δ prevented lenalidomide-induced upregulation of other co-stimulatory molecules important to B-cell antigen presentation 4 . We found that treatment with the PI3K-δ inhibitor CAL-101 was able to prevent the upregulation of CD40 and CD86 induced by lenalidomide (p-value=0.0102 and <0.0001, respectively) ( Fig. 2A) .
Similarly we found that inhibition of PI3K-δ could also prevent the increase in mRNA of CD40, CD86, CD154 and CD80 promoted by lenalidomide (p-value<0.009 for all genes) (Fig. 2B and data not shown). Activation of CLL cells by lenalidomide has also been shown to induce internalization of the CD20 antigen on CLL cells 21 similar to that observed in activated normal B-cells 23, 24 ; concurrent treatment with CAL-101 prevented this effect (p-value=0.0057) (Fig. 2A) .
The CD40-CD154 axis is important in allowing lenalidomide-treated CLL cells to promote (Fig. 2C ).
Cytokines such as basic fibroblast growth factor (b-FGF) [6] [7] [8] and vascular endothelial growth factor (VEGF) 6,9-11 support the survival of CLL cells. Moreover, it has been observed that circulating levels of b-FGF can correlate with response or non-response to therapy for CLL 2 .
Thus, we sought to determine if lenalidomide treatment of CLL cells in culture could promote conditions favoring enhanced tumor cell production of these factors. We found that lenalidomide treatment increased b-FGF mRNA in all patients (p-value=0.0004) and that coincubation with CAL-101 prevented this up-regulation (p-value<0.001) (Fig. 2D) . Similarly, we found that lenalidomide treatment increased VEGF mRNA in a subset (8 of 13) of patients, and that this effect was also reversed by CAL-101 co-treatment (p-value=0.002) (Fig. 2E ).
Our data demonstrate that the PI3K-δ pathway is involved in lenalidomide-mediated For 
